The Lightning-enabled device means that DarioHealth is now compatible with the latest Apple devices, including the brand-new iPhone 8 and iPhone X.

Apple iOS has just over 50% market share in the UK. With additional potential users, DarioHealth believes that it will now be able to increase UK-driven revenues and achieve greater market penetration.

This news comes shortly after the company’s recent announcement of receiving the Therapeutic Goods Administration (TGA) Mark in the Australian market for the same Lightning-enabled device. Sales of the device are expected to begin in Australia mid-January. DarioHealth says it expects to hear from the US Food and Drug Administration (FDA) about necessary clearance over the next few months.

“As the digital world continuously evolves, we are committed to offering people with diabetes the most up-to-date technology to manage the disease,” said Erez Raphael, chairman and CEO of DarioHealth.

“We are excited to begin sales of our lightning-enabled device in the UK and we look forward to doing the same in Australia and the US”.